Vesnarinone for Heart Failure

K. Swedberg, H. Wedel, D. Neely, A. Schwartz, A. M. Feldman, M. R. Bristow, W. W. Parmley, M. Packer

Research output: Contribution to journalLetter

2 Scopus citations


To the Editor: In the report by Feldman et al. (July 15 issue)1 we are concerned about the lack of agreement between the results of the two doses used in the trial. When the study was designed, it seemed plausible that the 120-mg dose would be more effective than the 60-mg dose. However, the opposite was found. We think it is important to combine the mortality data for the 87 patients receiving the higher dose of vesnarinone with those for the 239 patients receiving the lower dose, in addition to the analyses presented in the article. When this is done,…

Original languageEnglish (US)
Pages (from-to)64-66
Number of pages3
JournalNew England Journal of Medicine
Issue number1
StatePublished - Jan 6 1994


ASJC Scopus subject areas

  • Medicine(all)

Cite this

Swedberg, K., Wedel, H., Neely, D., Schwartz, A., Feldman, A. M., Bristow, M. R., Parmley, W. W., & Packer, M. (1994). Vesnarinone for Heart Failure. New England Journal of Medicine, 330(1), 64-66.